Pharmena SA
WSE:PHR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| PL |
P
|
Pharmena SA
WSE:PHR
|
41m PLN |
Loading...
|
|
| FR |
|
L'Oreal SA
PAR:OR
|
209.9B EUR |
Loading...
|
|
| UK |
|
Unilever PLC
LSE:ULVR
|
114.4B GBP |
Loading...
|
|
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.7T INR |
Loading...
|
|
| UK |
|
HALEON PLC
LSE:HLN
|
35.9B GBP |
Loading...
|
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
36.1B USD |
Loading...
|
|
| DE |
|
Beiersdorf AG
XETRA:BEI
|
22.7B EUR |
Loading...
|
|
| JP |
|
Kao Corp
TSE:4452
|
3T JPY |
Loading...
|
|
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR |
Loading...
|
|
| IN |
|
Dabur India Ltd
NSE:DABUR
|
901.4B INR |
Loading...
|
|
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD |
Loading...
|
Market Distribution
| Min | -9 940 700% |
| 30th Percentile | -3.7% |
| Median | 2.9% |
| 70th Percentile | 9.1% |
| Max | 196 605.3% |
Other Profitability Ratios
Pharmena SA
Glance View
PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. The company is headquartered in Lodz, Woj. Lodzkie and currently employs 24 full-time employees. The company went IPO on 2008-08-25. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Pharmena SA is -156.8%, which is below its 3-year median of 1 519.8%.
Over the last 3 years, Pharmena SA’s Net Margin has decreased from -13% to -156.8%. During this period, it reached a low of -1 268.3% on Dec 31, 2023 and a high of 9 964.6% on Jun 30, 2024.
